Top articles

• Nemeth G, Varga Z, Greff Z, Bencze G, Sipos A, Szantai-Kis C, Baska F, Gyuris A, Kelemenics K, Szathmary Z, Minarovits J, Keri G, Orfi L
  Novel, Selective CDK9 Inhibitors for the Treatment of HIV Infection.
  CURRENT MEDICINAL CHEMISTRY 18: pp. 342-358. (2011)
  IF: 4.630 (2010)
• Borbely G, Szabadkai I, Horvath Z, Marko P, Varga Z, Breza N, Baska F, Vantus T, Huszar M, Geiszt M, Hunyady L, Buday L, Orfi L, Keri G
  Small-Molecule Inhibitors of NADPH Oxidase 4.
  JOURNAL OF MEDICINAL CHEMISTRY 53:(18) pp. 6758-6762. (2010)
  IF: 5.207
• Petak I, Schwab R, Orfi L, Kopper L, Keri G
  Integrating molecular diagnostics into anticancer drug discovery.
  NATURE REVIEWS DRUG DISCOVERY 9:(7) pp. 523-535. (2010)
  IF: 28.712
• Kirti Sharma, Christoph Weber, Michaela Bairlein, Zoltán Greff, György Kéri, Jürgen Cox, Jesper V Olsen, Henrik Daub
  Proteomics strategy for quantitative protein interaction profiling in cell extracts.
  NATURE METHODS 6:(10) pp. 741-744. (2009)
  IF: 16.874
• Hegymegi-Barakonyi B, Eros D, Szantai-Kis C, Breza N, Banhegyi P, Szabo GV, Varkondi E, Petak I, Orfi L, Keri G
  Tyrosine kinase inhibitors - Small molecular weight compounds inhibiting EGFR.
  CURRENT OPINION IN MOLECULAR THERAPEUTICS 10:(3) pp. 308-321. (2009)
  IF: 3.452
• Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, Szabadkai I, Daub H, Keri G, Ullrich A
  AXL is a potential target for therapeutic intervention in breast cancer progression.
  CANCER RESEARCH 68:(6) pp. 1905-1915. (2008)
  IF: 7.514
• Daub H, Olsen JV, Bairlein M, Gnad F, Oppermann FS, Korner R, Greff Z, Keri G, Stemmann O, Mann M
  Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.
  MOLECULAR CELL 31:(3) pp. 438-448. (2008)
  IF: 12.903
• Wissing J, Jansch L, Nimtz M, Dieterich G, Hornberger R, Keri G, Wehland J, Daub H
  Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry.
  MOLECULAR & CELLULAR PROTEOMICS 6:(3) pp. 537-547. (2007)
  IF: 9.425
• Kéri Gy, Orfi L, Eros D, Hegymegi-Barakonyi B, Szántai-Kis Cs, Horváth Z, Wáczek F, Marosfalvy J, Szabadkai I, Pató J, Greff Z, Hafenbradl D, Daub H, Müller G, Klebl B, Ullrich A
  Signal Transduction Therapy with Rationally Designed Kinase Inhibitors.
  CURRENT SIGNAL TRANSDUCTION THERAPY 1:(1) pp. 67-95. (2006)
• Keri G, Szekelyhidi Z, Banhegyi P, Varga Z, Hegymegi Barakonyi B, Szantai Kis C, Hafenbradl D, Klebl B, Muller G, Ullrich A, Eros D, Horvath Z, Greff Z, Marosfalvi J, Pato J, Szabadkai I, Szilagyi I, Szegedi Z, Varga I, Waczek F, Orfi L
  Drug discovery in the kinase inhibitory field using the Nested Chemical Library (TM) technology.
  ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES 3:(5) pp. 543-551. (2005)
  IF: 2.060
• Godl K, Gruss O J, Eickhoff J, Wissing J, Blencke S, Weber M, Degen H, Brehmer D, Orfi L, Horvath Z, Keri G, Muller S, Cotten M, Ullrich A, Daub H
  Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling.
  CANCER RESEARCH 65:(15) pp. 6919-6926. (2005)
  IF: 7.616
• Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, Muller S, Klebl B, Cotten M, Keri G, Wissing J, Daub H
  Cellular targets of gefitinib.
  CANCER RESEARCH 65:(2) pp. 379-382. (2005)
  IF: 7.616
• Blencke S, Zech B, Engkvist O, Greff Z, Orfi L, Horvath Z, Keri G, Ullrich A, Daub H
  Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.
  CHEMISTRY & BIOLOGY 11:(5) pp. 691-701. (2004)
  IF: 5.725